This 2017 IPO Still Boasts Massive Growth Potential

Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) stock has nearly doubled from its IPO price in 2017, and the biotech’s product candidates should really excite investors.

| More on:
Dad and son having fun outdoor. Healthy living concept

Image source: Getty Images

The health care sector has received more attention over the past decade, and with good reason. New technology and breakthroughs are revolutionizing the sector, and aging demographics in the western world have put intense pressure on the public and private sphere. Biopharmaceuticals, which are pharmaceutical products with biological components, are the fastest-growing subsector in the industry.

The U.S. healthcare sector dwarfs our domestic industry, and this is reflected by the breadth of equities available south of the border. However, the TSX still offers some great options for investors hunting for growth. Today we will focus on a Vancouver-based biotechnology company that launched its initial public offering in May 2017.

Zymeworks

Zymeworks (TSX:ZYME)(NYSE:ZYME) stock had climbed 64% in 2019 as of close on July 9. At the beginning of this year, I’d recommended Zymeworks as one of my top growth stocks for a TFSA to kick off 2019.

Shares have gained considerable momentum in the spring and early summer on the back of some promising news. The stock has nearly doubled from its initial IPO price.

The promising news broke in the month of May. Zymeworks announced that it had opened Phase 2 trials for its lead product candidate, ZW25. Its other proprietary drug candidate, ZW49, has been pushed forward into Phase 1 clinical trials.

ZW25 has proven effective in treating patients with a variety of HER2-positive cancers. In the Phase 2 trial Zymeworks will evaluate ZW25 for the first-line treatment of HER2-positive gastroesophageal cancers. There is a long road ahead, but the drug holds massive market potential if it can continue to demonstrate positive results going forward.

Investors should keep this long-time horizon in mind when considering Zymeworks as an addition in 2019. Still, Zymeworks has built a deep pipeline that’s boosted its price point in the near term. In the first quarter, the company reported revenues of $11.9 million compared to $0.04 million in the prior year.

Predictably, research and development payments increased to $17.5 million compared to $13.1 million for the same period in 2018.

Zymeworks saw its net loss decrease to $13.6 million compared to $21.2 million in Q1 2018. It received a boost from increased revenue and interest income.

Broad expansion in key markets

ZW25 has demonstrated anti-tumour activity in pre-clinical models of breast and gastric cancers. The World Health Organization reported that approximately 627,000 women succumbed to breast cancer in 2018. The rising incidence of breast cancer, which represented 15% of all cancer deaths worldwide in 2018, is driving investment and research.

Recent research has shown the growth of the breast cancer therapeutics market as we move into the next decade. A 2019 report from Fortune Business Insights forecasts the market to exhibit 10.2% CAGR between 2018 and 2026. Zion Market Research published a report in March that examined the global breast cancer drugs market. It projected the market to post a CAGR of 10.55% between 2019 and 2025.

At the time of this writing, Zymeworks boasted an RSI of 70, putting the stock in technically overbought territory. I’m very bullish on Zymeworks going forward, but value investors may want to exercise patience in order to pick out a more attractive entry point.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »